Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.

about

Standing in the Shifting Sands of Molecular Targeting and Precision Medicine Is the Oasis of 21st-Century Oncology Therapeutics.

P2860

Q50045474-3C247CBE-7EC2-4D83-BCBE-3D500C97DF96

P2860

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.

Item

http://www.wikidata.org/entity/Q47969034

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Clinical Pharmacology Tools an ...... tinuous Risk-Benefit Approach.

@en

Clinical Pharmacology Tools an ...... tinuous Risk-Benefit Approach.

@nl

type

Item

label

Clinical Pharmacology Tools an ...... tinuous Risk-Benefit Approach.

@en

Clinical Pharmacology Tools an ...... tinuous Risk-Benefit Approach.

@nl

prefLabel

Clinical Pharmacology Tools an ...... tinuous Risk-Benefit Approach.

@en

Clinical Pharmacology Tools an ...... tinuous Risk-Benefit Approach.

@nl

P1476

Clinical Pharmacology Tools an ...... tinuous Risk-Benefit Approach.

@en

P2093

Julie M Bullock

http://www.w3.org/2001/XMLSchema#string

Sanela Bilic

http://www.w3.org/2001/XMLSchema#string

Tiffany Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating biomarkers to monitor cancer progression and treatment

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Costs associated with adverse events in patients with metastatic renal cell carcinoma.

Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.

The determination and interpretation of the therapeutic index in drug development.

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

Antibody pharmacokinetics and pharmacodynamics.

On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.

P304

S105-S115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.908

http://www.w3.org/2001/XMLSchema#string

P478

57 Suppl 10

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28921642

http://www.w3.org/2001/XMLSchema#string

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.

about

P2860

P2860

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698